Hi - Tech Pharmacal (HITK)
Hi - Tech Pharmacal Profit Margin: 19.43%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
HITK Profit Margin Rankings
| Overall | 88th percentile | 513 of 4390 |
| Sector | 91st percentile | 42 of 469 in Healthcare |
| Industry | 83rd percentile | 2 of 12 in Drugs - Generic |
HITK Profit Margin Range, Past 5 Years
| Minimum | -28.50% | Jul 2007 |
| Maximum | 24.50% | Jul 2011 |
| Average | 11.95% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these HITK related companies
HITK News
$HITK added the 1/4 back at 29 from sell on 12/5/11 http://stks.co/3xYw WSB #2
about 6 days ago by WallStreetBean
about 6 days ago by WallStreetBean
Hi-Tech Pharmacal to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 14, 7:00AM Business Wire
May 14, 7:00AM Business Wire
Standpoint Research Starts Hi Tech Pharmacal (HITK) at Buy; Large Pipeline
May 07, 10:30AM Street Insider
May 07, 10:30AM Street Insider
BeanScreen for May 1, 2012 | via @wallstreetbean http://stks.co/3bD3 $RES $HITK $EZPW $CF $CEO $LULU
about 28 days ago by STNet
about 28 days ago by STNet
$HITK forms bearish "Double Top" chart pattern. http://stks.co/3N6j
about 43 days ago by RecogniaEvents
about 43 days ago by RecogniaEvents
WSB20 April leaders: $TNH $BVN $CF losers: $RES $HITK $BKE http://stks.co/3Lbu
about 45 days ago by WallStreetBean
about 45 days ago by WallStreetBean
BeanScreen LinkHouse – Week in Review (April 9-13, 2012) | via @wallstreetbean http://stks.co/3LYW $RES $HITK $BKE $LULU $CHL $RGR
about 46 days ago by STNet
about 46 days ago by STNet
$HITK 3rd bounce off support, volume slowed, 36.64 stop entry ...and im smiling, trgt- circa 44
about 64 days ago by garbucci
about 64 days ago by garbucci
Generic Drug industry group with the RS line in new lows before price. $PRGO $HITK
about 72 days ago by hertcapital
about 72 days ago by hertcapital
RT @WallStreetBean: BeanScreen LinkHouse - Week in Review http://stks.co/2lpw $CEO $HITK $RES $AAPL $BKE
about 81 days ago by WallStJesus
about 81 days ago by WallStJesus
BeanScreen LinkHouse - Week in Review http://stks.co/2lot $CEO $HITK $RES $AAPL $BKE
about 81 days ago by WallStreetBean
about 81 days ago by WallStreetBean
Canaccord Genuity Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Updating Model
Mar 09, 10:09AM Street Insider
Mar 09, 10:09AM Street Insider
Needham & Company Maintains a 'Hold' on Hi Tech Pharmacal (HITK); Upside Momentum Stalls Out In 3Q
Mar 09, 7:49AM Street Insider
Mar 09, 7:49AM Street Insider
Hi-Tech Lo-Balls Earnings | via @wallstreetbean http://stks.co/2jhP $HITK
about 82 days ago by STNet
about 82 days ago by STNet
Hi-Tech Pharmacal Reports Sales of $55.6 Million and EPS of $0.79 for the Third Quarter Ended January 31, 2012
Mar 08, 7:05AM Business Wire
Mar 08, 7:05AM Business Wire
Hi-Tech Pharmacal (HITK) to Acquire Dynova Labs' Nasal Spray Products in $2.5M Deal
Mar 08, 7:04AM Street Insider
Mar 08, 7:04AM Street Insider
Hi-Tech Pharmacal Acquires a Line of Branded Homeopathic Nasal Spray Products
Mar 08, 7:02AM Benzinga
Mar 08, 7:02AM Benzinga
Notable #EarningsReports Wednesday AfterHours: $FTK Friday PreMarket: $HITK
about 83 days ago by CapitalistBull
about 83 days ago by CapitalistBull
BeanScreen LinkHouse – Week in Review http://stks.co/2f8B $CEO $GRMN $AAPL $HITK $BKE $INTC
about 86 days ago by WallStreetBean
about 86 days ago by WallStreetBean
$HITK http://stks.co/2ewW over 43 has a Measured Move to 47 but topping tails, may not get a chance
about 87 days ago by harmongreg
about 87 days ago by harmongreg
Hi-Tech Pharmacal to Release Third Quarter Earnings and Hold Conference Call on March 8, 2012
Mar 02, 11:59AM Business Wire
Mar 02, 11:59AM Business Wire
RT @SonaliVerma Smart returns Foolish Eight portfolio: http://stks.co/2eBw $HITK $MELI $RGR $OZRK $LULU $LLL.CA $BPI $RIC $ASPS $GOLD $MDF
about 88 days ago by BigKarma
about 88 days ago by BigKarma
Smart returns from Foolish Eight portfolio: http://stks.co/2e2R $HITK $MELI $RGR $OZRK $LULU $LLL.CA $BPI $RIC $ASPS $GOLD $MDF #investing
about 88 days ago by SonaliVerma
about 88 days ago by SonaliVerma
BeanScreen for March 1, 2012 http://stks.co/2cZ8 $CEO $HITK $RES $EZPW $AAPL $LULU $GRMN
about 90 days ago by WallStreetBean
about 90 days ago by WallStreetBean
Hi-Tech Pharmacal to Present at the 2012 RBC Capital Markets’ Global Healthcare Conference
Feb 28, 6:05PM Business Wire
Feb 28, 6:05PM Business Wire
Canaccord Genuity Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Positive After Meeting with Mgmt
Feb 01, 10:09AM Street Insider
Feb 01, 10:09AM Street Insider
Hi-Tech Pharmacal (HITK) Gets FDA Approval for Generic Lorazepam Intensol ANDA
Jan 31, 7:05AM Street Insider
Jan 31, 7:05AM Street Insider
Hi-Tech Pharmacal’s ECR Pharmaceuticals Subsidiary Launches Hylase® Wound Gel
Jan 18, 8:00AM Business Wire
Jan 18, 8:00AM Business Wire
Canaccord Genuity Reiterates a 'Buy' on Hi Tech Pharmacal (HITK) on Sell-off Post Checks, Management Meeting
Jan 11, 8:49AM Street Insider
Jan 11, 8:49AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HITK | 29.28 | -0.28 | -0.95% | 383.98M |
| HIMX | 2.02 | -0.02 | -0.98% | 356.27M |
| HILL | 1.205 | +0.03 | +2.12% | 68.29M |
| HIL | 2.98 | -0.01 | -0.33% | 115.12M |
| HIHO | 1.48 | -0.04 | -2.68% | 5.594M |
| HIH | 8.60 | +0.05 | +0.58% | |
| HIG | 17.72 | +0.39 | +2.25% | 7.629B |
| HIFS | 58.20 | +0.12 | +0.21% | 122.80M |
| HIF | 9.54 | -0.10 | -1.04% | |
| HIBB | 56.46 | -0.59 | -1.03% | 1.506B |